seriou
viral
infect
common
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
hsct
occur
major
allograft
recipi
fatal
sever
infect
may
prolong
recurr
add
substanti
cost
human
financi
procedur
mani
featur
allogen
hsct
contribut
high
rate
viral
diseas
cytotox
immunosuppress
drug
administ
pretranspl
elimin
host
hematopoieticimmun
system
associ
malign
delay
recapitul
immun
ontogeni
potenti
induct
immun
anergi
upon
exposur
immatur
system
activ
viral
infect
immunosuppress
drug
given
prevent
graft
versu
host
diseas
gvhd
effect
gvhd
serv
make
hsct
recipi
vulner
diseas
endogen
latent
exogen
commun
virus
incap
control
quickli
effect
normal
individu
past
year
great
stride
made
identifi
implement
effect
therapeut
agent
prevent
treatment
mani
seriou
viru
infect
afflict
hsct
recipi
combin
effect
agent
rapid
molecular
analys
detect
earli
reactiv
latent
infect
possibl
transform
outcom
patient
cytomegaloviru
cmv
epstein
barr
viru
ebv
agent
ganciclovir
rituximab
respect
use
control
cmv
ebv
caus
seriou
fatal
ill
despit
advanc
earli
detect
prompt
treatment
viral
ill
remain
major
threat
might
expect
improv
viral
prophylaxi
treatment
encourag
clinician
extend
rang
patient
hsct
offer
cur
option
diseas
high
proport
patient
transplant
lack
sibl
ident
human
leukocyt
antigen
hla
major
histocompat
antigen
necessit
use
altern
stem
cell
sourc
includ
match
unrel
donor
haploident
relat
donor
cord
blood
unit
patient
may
requir
donor
cell
remov
infus
stem
cell
prepar
may
need
receiv
intens
prolong
post
transplant
immunosuppress
increas
suscept
viral
diseas
prolong
durat
enhanc
suscept
moreov
consider
success
ganciclovir
rituximab
cmv
ebv
diseas
yet
follow
avail
addit
agent
effect
safe
treat
mani
viru
infect
transplant
patient
suscept
tabl
even
pharmacolog
therapi
avail
agent
costli
associ
signific
toxic
may
lead
outgrowth
mutant
sinc
none
agent
improv
immun
root
caus
viral
infect
diseas
frequent
recur
termin
treatment
review
describ
immunotherapeut
strategi
explor
group
achiev
safe
effect
sustain
antivir
prophylaxi
treatment
follow
hsct
discuss
success
limit
approach
first
adopt
transfer
studi
allogen
hsct
base
premis
peripher
blood
stem
cell
donor
would
contain
cell
abl
mediat
antivir
activ
hsct
recipi
expect
cell
would
expand
recipi
adopt
transfer
provid
protect
immun
term
antivir
activ
provid
donor
prior
viru
exposur
donor
peripher
blood
inde
contain
memori
cell
specif
broad
rang
virus
reflect
exposur
host
array
pathogen
dli
prove
effect
treatment
adenoviru
adv
infect
lymphoprolif
diseas
ptld
unfortun
broader
applic
limit
low
frequenc
cell
compar
much
higher
frequenc
alloreact
cell
caus
gvhd
particular
concern
hla
mismatch
recipi
risk
viral
ill
circul
cell
may
alloreact
frequenc
cell
given
antivir
specif
may
mani
log
lower
fig
even
dli
use
success
treat
ebv
infect
high
rate
gvhd
observ
cell
reactiv
mani
common
commun
virus
parainfluenza
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
frequent
undetect
peripher
blood
stem
cell
donor
make
approach
high
risk
wide
use
prevent
treat
associ
viral
diseas
cell
select
anerg
exploit
requir
cell
receiv
signal
secondari
signal
becom
success
activ
prolifer
one
costimulatori
signal
deliv
molecul
cell
apc
receptor
cell
blockad
interact
use
fusion
protein
monoclon
antibodi
receptor
tcr
engag
demonstr
induc
hyporespons
cell
guinan
et
al
success
use
blockad
strategi
clinic
two
day
prior
transplant
harvest
haploident
donor
marrow
incub
mononuclear
cell
presenc
either
monoclon
antibodi
anerg
cell
administ
time
hsct
two
pilot
studi
found
even
product
contain
larg
number
alloanerg
donor
cell
rang
cellskg
accept
engraft
less
sever
acut
gvhd
histor
control
recipi
haploident
stem
cell
replet
unmanipul
cell
addit
report
treat
subject
rapid
immun
reconstitut
histor
control
detect
vivo
expans
cell
altern
alloreact
cell
may
physic
remov
donor
graft
prior
infus
sever
group
donor
cell
apc
variou
origin
includ
peripher
blood
mononuclear
cell
pbmc
activ
cell
lymphoblastoid
cell
line
dendrit
cell
dc
fibroblast
cell
within
donor
cell
popul
stimul
recipi
apc
subsequ
upregul
activ
marker
prolifer
reactiv
cell
select
elimin
coupl
monoclon
antibodi
target
activ
antigen
immunotoxin
induct
apoptosi
photodynam
purg
photodynam
approach
use
clinic
et
al
use
conjug
ricin
chain
allodeplet
haploident
n
match
unrel
n
donor
cell
infus
earli
day
cohort
pediatr
patient
patient
receiv
multipl
infus
allodeplet
cellskg
gvhd
prophylaxi
even
highest
dose
level
allodeplet
cell
found
safe
contrast
earlier
studi
report
gvhd
ii
patient
infus
unmanipul
donor
cellskg
addit
investig
found
evid
allodeplet
cell
retain
compon
two
patient
ebv
cmv
develop
high
frequenc
circul
precursor
postinfus
clear
respect
infect
solomon
et
al
appli
approach
adult
infus
patient
median
year
haploident
cell
also
allodeplet
immunotoxin
group
patient
would
consid
high
risk
develop
gvhd
fact
eight
patient
develop
complic
mild
moder
gvhd
grade
steroid
respons
six
sever
two
develop
gvhd
appear
correl
effici
allodeplet
group
also
demonstr
infus
cell
haploident
hsct
recipi
safe
threshold
least
allodeplet
cellskg
requir
acceler
antivir
recoveri
recent
mielk
et
al
use
photodynam
purg
prepar
allodeplet
cell
infus
use
photoact
rhodamin
deriv
effici
diffus
rest
activ
cell
rest
cell
activ
extrud
dye
select
retain
mitochondria
activ
cell
due
inactiv
multidrug
transport
activ
cell
sensit
visibl
light
nm
result
mitochondri
oxid
cell
death
take
advantag
properti
mielk
et
al
donor
cell
activ
cell
follow
addit
exposur
visibl
light
sibl
hsct
recipi
receiv
dose
photodeplet
cellskg
day
unfortun
result
disappoint
acut
chronic
gvhd
frequent
infecti
complic
associ
viral
cmv
adv
bk
viru
rsv
bacteri
fungal
pathogen
common
unexpectedli
prolong
sever
trial
halt
studi
unclear
whether
sever
gvhd
associ
variabl
infus
photodeplet
product
overal
studi
demonstr
feasibl
allodeplet
therapi
also
emphas
import
choos
optim
stimul
cell
achiev
robust
alloactiv
impact
variabl
effici
allodeplet
vivo
safeti
narrow
unpredict
therapeut
window
desir
antivir
activ
unwant
gvhd
moreov
sinc
cell
specif
major
viral
pathogen
circul
frequenc
lower
ebv
cmv
fig
like
extrem
high
dose
allodeplet
cell
would
need
provid
full
spectrum
protect
even
allodeplet
cell
dose
requir
would
like
exceed
gvhd
threshold
final
allodeplet
approach
present
reliabl
use
donor
recipi
haploident
fewer
hla
dispar
differ
minor
histocompat
antigen
eg
hla
match
sibl
transplant
degre
alloactiv
produc
mix
lymphocyt
cultur
insuffici
consist
remov
alloreact
cell
consequ
ratio
viral
reactiv
alloreact
cell
suffici
improv
obtain
benefici
antivir
effect
absenc
increas
gvhd
altern
ex
vivo
allodeplet
administ
donor
cell
incorpor
suicid
safeti
switch
activ
event
gvhd
allow
recipi
take
full
advantag
antivir
benefit
associ
donor
infus
moreov
suicid
switch
function
activ
cell
patient
gvhd
viral
infect
induct
suicid
may
deplet
alloreact
compon
spare
cell
capabl
respond
futur
viru
reactiv
infect
wide
test
vivo
allodeplet
approach
use
thymidin
kinas
gene
herp
simplex
viru
tk
express
transgen
cell
catalyz
phosphoryl
prodrug
ganciclovir
activ
agent
transform
final
triphosph
form
cellular
kinas
drug
act
gtp
analog
thu
inhibit
dna
chain
elong
kill
divid
cell
sever
phase
studi
shown
ganciclovir
administr
use
deplet
transfer
cell
vivo
advers
event
relat
gene
transfer
report
howev
induct
transgen
cell
death
may
requir
mani
day
usual
incomplet
potenti
delay
clinic
benefit
addit
sinc
ganciclovir
requir
cell
elimin
preclud
use
antivir
agent
eg
treatment
cmv
highli
suscept
patient
popul
final
tk
gene
product
immunogen
exampl
rel
immun
compet
patient
post
hsct
mount
respons
lead
prematur
unintent
elimin
infus
cell
despit
potenti
limit
phase
ii
clinic
studi
shown
cell
consist
benefit
immun
reconstitut
gvhd
control
ganciclovir
administr
approach
evalu
multicent
phase
iii
studi
hope
allow
licensur
import
approach
investig
altern
transduc
allodeplet
cell
retrovir
vector
encod
induc
human
caspas
suicid
gene
select
marker
truncat
human
enabl
enrich
transduc
cell
gene
product
activ
exposur
small
molecul
chemic
induc
dimer
cid
lead
rapid
death
trigger
intrins
mitochondri
apoptosi
pathway
gave
cell
haploident
pediatr
hsct
recipi
patient
develop
gvhd
gave
singl
dose
dimer
drug
found
cid
treatment
elimin
infus
transgen
cell
within
min
log
deplet
next
h
patient
gvhd
respond
fulli
recur
even
residu
transgen
cell
recov
cell
howev
retain
antivir
activ
suggest
select
spare
cell
activ
alloreact
cell
caus
gvhd
found
evid
immun
respons
transgen
cell
use
otherwis
bioinert
small
molecul
dimer
activ
allow
retent
import
antivir
agent
includ
ganciclovir
therapeut
use
cell
detect
antigen
via
tcr
interact
peptid
bound
molecul
present
surfac
apc
interact
weak
typic
last
longer
second
physiolog
temperatur
advanc
past
year
howev
produc
multimer
form
solubl
molecul
enhanc
avid
util
ex
vivo
visual
select
cell
bear
cognat
tcr
date
two
distinct
multim
format
tetram
pentam
use
select
cell
adopt
transfer
tetram
consist
four
hla
molecul
held
tetrahedr
configur
typic
allow
complex
bind
cognat
tcr
fig
five
group
howev
arrang
planar
configur
five
complex
avail
tcr
bind
therebi
increas
bind
sensit
avid
cobbold
et
al
first
use
cell
clinic
select
cell
sinc
cell
specif
clinic
import
viru
found
high
frequenc
healthi
seroposit
individu
typic
pool
facilit
direct
isol
ex
vivo
investig
use
panel
cmv
tetram
select
specif
cell
nine
sct
donor
administ
six
recipi
match
relat
donor
transplant
three
recipi
match
unrel
transplant
cmv
reactiv
although
infus
product
compos
exclus
cell
cell
expand
sever
log
vivo
eight
nine
case
cmv
viral
load
becam
undetect
post
transfer
case
cmv
diseas
seen
uhlin
et
al
use
pentam
isol
cell
mother
cord
blood
transplant
recipi
base
share
haplotyp
avail
pentam
detect
specif
popul
peripher
blood
investig
use
two
epitop
ebv
lytic
latent
select
specif
cell
adopt
transfer
directli
select
cell
expand
postinfus
produc
complet
clinic
respons
although
antivir
protect
sinc
recur
month
diseas
erad
second
infus
cell
group
subsequ
use
multim
select
isol
cell
either
cryopreserv
donor
materi
third
parti
donor
peripher
blood
treat
eight
patient
cmv
n
pentam
adv
n
peptid
ebv
n
peptid
infect
allogen
hsct
six
eight
patient
show
decreas
viral
titer
within
week
receiv
select
cell
recent
research
prepar
streptam
clinic
applic
multim
bind
complex
hla
molecul
tcr
cell
revers
addit
competitor
molecul
caus
streptam
monomer
rapid
releas
streptam
cell
mean
final
infus
product
indistinguish
untreat
cell
consequ
european
medicin
agenc
consid
cell
therapi
medicin
product
requir
substanti
less
test
prior
clinic
use
agent
classifi
atmp
recent
schmitt
et
al
report
first
clinic
streptam
experi
two
patient
refractori
cmv
singl
infus
cellskg
puriti
frequenc
cell
patient
increas
maximum
peripher
blood
cell
patient
receiv
lower
cell
dose
cellskg
nevertheless
detect
increas
cell
expand
cell
confirm
donor
origin
analysi
donor
chimer
repeat
analysi
receptor
excis
circl
type
clinic
infus
result
cmv
clearanc
without
gvhd
clinic
success
hold
promis
multim
select
cell
current
remain
limit
patient
infect
immunolog
virus
eg
cmv
ebv
defin
epitop
known
element
donor
rel
high
frequenc
circul
reactiv
cell
peripher
blood
otherwis
suffici
larg
start
number
donor
pbmc
may
readili
avail
eg
donor
unrel
recipi
altern
mean
cell
rapidli
select
adopt
transfer
base
abil
produc
secret
effector
cytokin
date
cell
secret
manner
use
clinic
captur
techniqu
base
premis
cell
capabl
secret
follow
h
antigen
exposur
popul
specif
captur
label
cell
monoclon
antibodi
conjug
antibodi
follow
magnet
select
microbead
thu
unlik
multim
select
approach
use
select
cell
hla
unrestrict
manner
feuchting
et
al
first
use
select
platform
mean
treat
adv
infect
set
adv
particularli
high
incid
pediatr
hsct
remain
signific
caus
morbid
mortal
immunocompromis
individu
may
produc
pneumonia
hemorrhag
cystiti
nephriti
coliti
hepat
enceph
sever
report
shown
clearanc
infect
associ
detect
cell
thu
studi
feuchting
et
al
stimul
donor
pbmc
match
relat
n
match
unrel
n
mismatch
unrel
n
haploident
n
adv
lysat
overnight
follow
magnet
select
popul
infus
cell
nine
pediatr
patient
system
adv
infect
defin
persist
recurr
adv
dna
peripher
blood
andor
stool
week
antivir
chemotherapi
lack
cell
infus
found
safe
despit
small
number
infus
polyclon
cell
rang
cellskg
mean
mean
associ
clinic
benefit
sinc
five
six
evalu
patient
show
signific
decreas
viral
load
peripher
blood
stool
correspond
increas
frequenc
cell
blood
studi
group
appli
approach
treat
chemorefractori
cmv
diseas
reactiv
h
stimul
immunodomin
protein
captur
cell
mean
cellskg
infus
patient
match
relat
n
match
unrel
n
mismatch
unrel
n
haploident
n
infus
singl
case
gvhd
report
fifteen
infus
patient
clear
cmv
viremia
signific
reduct
log
viral
load
pegg
et
al
also
report
adopt
transfer
cell
diseas
prophylaxi
treatment
studi
protein
peptid
pool
use
stimul
cell
median
cellskg
infus
earli
median
day
expans
popul
detect
vivo
howev
acut
gvhd
observ
eight
patient
grade
two
requir
system
steroid
therapi
three
patient
develop
extens
chronic
gvhd
captur
also
use
obtain
therapeut
effect
cell
moosmann
et
al
select
cell
follow
h
exposur
hla
class
peptid
deriv
ebv
antigen
five
latent
antigen
four
immedi
earlyearli
antigen
two
latestructur
antigen
full
set
peptid
use
gener
stimul
pool
donor
irrespect
individu
hla
haplotyp
captur
cell
given
six
allogen
hsct
recipi
develop
progress
follow
day
convent
therapi
includ
reduct
immunosuppress
administr
rituximab
cidofovir
three
patient
respond
three
multiorgan
dysfunct
time
transfer
show
nolow
activ
postinfus
fail
respond
icheva
et
al
took
similar
approach
focus
target
ebv
antigen
base
central
role
maintain
viral
persist
univers
express
fact
shown
contain
immunodomin
epitop
investig
stimul
donor
pbmc
either
whole
protein
overlap
peptid
pool
gave
captur
cell
patient
toxic
observ
eight
patient
show
vivo
expans
cell
associ
clinic
virolog
respons
seven
defin
decreas
viral
load
log
resolut
ptld
two
patient
vivo
expans
absent
clinic
improv
observ
clinic
trial
approach
shown
safe
produc
clinic
activ
cmv
adv
ebv
avail
univers
select
agent
use
irrespect
hla
haplotyp
rather
individu
multim
made
viral
epitop
hla
polymorph
abil
select
cell
rather
class
cell
potenti
advantag
select
techniqu
nevertheless
multim
select
techniqu
requir
larg
volum
start
donor
blood
even
small
number
captur
cell
obtain
limit
crucial
puriti
potenc
test
requir
prior
patient
transfer
consequ
approach
restrict
virus
high
circul
precursor
frequenc
immun
recoveri
hsct
also
safe
enhanc
infus
cell
vst
select
amplifi
ex
vivo
use
repetit
round
stimul
apc
express
target
viral
antigen
vitro
stimul
viral
antigen
select
enrich
cell
correspondingli
dilut
alloreact
cell
mean
even
low
frequenc
cell
obtain
substanti
number
small
quantiti
peripher
blood
strategi
produc
vst
direct
virus
circul
frequenc
practic
threshold
requir
either
multim
captur
assay
ex
vivo
expans
cell
requir
identif
immunodomin
antigen
target
virus
induc
protect
vst
well
deliveri
system
transfer
antigen
effect
apc
avoid
expand
alloreact
cell
apc
use
gener
vst
must
autolog
express
hla
molecul
present
peptid
apc
must
also
express
costimulatori
molecul
requir
support
robust
activ
expans
reagent
must
also
compliant
current
good
manufactur
practic
cgmp
cell
therapi
limit
use
cell
type
antigen
sourc
reagent
final
time
requir
produc
test
releas
expand
product
signific
mani
obstacl
limit
broader
applic
approach
describ
progress
surmount
ebv
ubiquit
human
herpesviru
adult
popul
seroposit
indic
previou
infect
primari
infect
viru
persist
latent
form
b
lymphocyt
epitheli
cell
nasopharynx
period
replic
reactiv
b
cell
tightli
control
strong
viral
respons
circul
cell
normal
ebv
seroposit
individu
may
specif
ebv
transplant
immun
impair
b
cell
would
normal
control
effect
cytotox
respons
outgrow
result
risk
complic
hsct
rang
risk
factor
includ
use
stem
cell
product
higher
degre
donor
recipi
use
globulin
atg
reduc
intens
regimen
ptld
develop
hsct
usual
deriv
donor
b
cell
recipi
origin
particularli
patient
receiv
condit
regimen
includ
atg
alemtuzimab
campath
receiv
cord
blood
transplant
outgrow
tumor
cell
highli
immunogen
express
nine
latent
ebv
antigen
sinc
almost
transplant
donor
ebv
seroposit
high
frequenc
circul
ebv
specif
precursor
good
target
diseas
test
activ
ex
vivo
expand
viru
antigen
specif
cell
earli
use
select
deplet
monoclon
antibodi
reduc
risk
gvhd
patient
receiv
transplant
match
unrel
donor
mismatch
famili
member
patient
develop
ebv
ptld
therefor
devis
strategi
prevent
treat
complic
infus
cell
gener
stimul
donor
mononuclear
cell
irradi
ebv
transform
donor
lcl
lcl
could
easili
gener
donor
incub
laboratori
strain
ebv
excel
apc
pattern
viral
gene
express
outgrow
tumor
cell
line
grown
stimul
lcl
polyclon
contain
recogn
multipl
latent
earli
lytic
cycl
ebv
antigen
review
experi
administ
cell
gener
methodolog
prophylaxi
high
risk
patient
treatment
patient
establish
ptld
tabl
patient
receiv
vst
prophylaxi
none
develop
ptld
compar
incid
control
thirteen
patient
receiv
cell
activ
diseas
achiev
sustain
complet
remiss
first
patient
line
genet
mark
retrovir
vector
encod
neomycin
resist
gene
enabl
us
track
cell
show
could
expand
log
persist
year
persist
may
bolster
infus
lymphopen
recipi
homeostat
mechan
promot
lymphoid
expans
continu
stimul
period
ebv
reactiv
anim
studi
also
suggest
presenc
cell
infus
line
import
persist
access
memori
pool
infus
although
patient
bulki
diseas
observ
revers
inflammatori
reaction
diseas
site
due
infiltr
activ
cell
note
infus
cell
alloreact
de
novo
gvhd
infus
similar
respons
rate
seen
anoth
studi
memori
sloan
ketter
cancer
center
mskcc
doubrovina
et
al
treat
patient
activ
ptld
cell
show
complet
respons
cell
given
three
patient
fail
respond
recogn
lcl
transform
laboratori
strain
use
stimul
strain
ebv
express
patient
tumor
similarli
one
patient
studi
initi
respons
progress
found
express
ebv
variant
delet
immunodomin
epitop
recogn
infus
line
infus
line
abl
target
parent
tumor
cell
tumor
cell
delet
subsequ
grew
anoth
patient
mskcc
seri
donor
vst
line
skew
respons
ebv
antigen
hla
antigen
present
donor
tumor
deriv
recipi
cell
patient
subsequ
respond
third
parti
line
match
fewer
antigen
strong
ebv
activ
share
antigen
experi
emphas
import
ascertain
whether
ptld
donor
recipi
origin
infus
line
antivir
activ
share
antigen
result
studi
confirm
therapi
use
line
gener
use
lcl
stimul
cell
safe
effect
prophylaxi
treatment
ptld
hsct
strategi
implement
multipl
institut
limit
time
taken
gener
lcl
line
around
week
vst
line
week
furthermor
illustr
use
laboratori
strain
ebv
gener
lcl
line
may
stimul
line
recogn
ebv
strain
make
move
approach
licens
studi
difficult
cmv
latent
immunocompet
individu
usual
caus
asymptomat
infect
howev
reactiv
cmv
immunocompromis
individu
result
signific
morbid
mortal
clinic
manifest
includ
interstiti
pneumon
gastroenter
fever
hepat
enceph
retin
immunocompet
host
cell
play
import
role
immun
protect
primari
infect
subsequ
reactiv
therefor
number
group
investig
whether
adopt
transfer
vitro
expand
vst
provid
protect
immunodefici
phase
follow
hsct
pioneer
work
walter
et
al
use
fibroblast
infect
strain
cmv
stimul
donor
cell
follow
clone
isol
cytolyt
cell
adopt
transfer
cell
administ
prophylact
recipi
transplant
weekli
interv
dose
escal
day
major
patient
lack
activ
prior
infus
activ
subsequ
detect
recipi
tcr
clonotyp
studi
show
transfer
cell
persist
least
week
progress
declin
patient
develop
concomit
endogen
respons
observ
highlight
import
helper
cell
sustain
antivir
activ
vivo
neither
cmv
viremia
diseas
develop
treat
patient
recent
group
perform
phase
ii
studi
clone
combin
infus
prophylact
cmv
seroposit
hsct
recipi
infus
safe
immedi
augment
immun
perruccio
et
al
also
prepar
clone
use
donor
pbmc
load
cmv
lysat
stimulu
studi
investig
exclus
gener
clone
infus
haploident
hsct
recipi
dose
rang
cellskg
cell
prove
safe
vivo
infus
acceler
recoveri
endogen
cell
control
cmv
antigenemia
altern
infus
clone
limit
divers
antivir
specif
group
use
polyclon
cell
direct
broader
array
cmv
antigen
epitop
prevent
treat
cmv
infect
exampl
einsel
et
al
gener
line
use
donor
pbmc
load
cmv
lysat
stimulu
result
vst
contain
cell
infus
eight
match
mismatch
relat
hsct
recipi
lack
endogen
immun
suffer
cmv
viremia
defin
presenc
cmv
dna
peripher
blood
minimum
week
antivir
chemotherapi
infus
safe
result
signific
viral
load
reduct
seven
evalu
patient
durabl
five
two
patient
highest
viral
load
howev
antivir
effect
transient
one
patient
respond
second
vst
infus
wherea
succumb
fatal
cmv
enceph
refus
second
dose
cell
similar
success
outcom
report
pegg
et
al
use
dc
load
inactiv
cmv
antigen
stimul
pbmc
allogen
hsct
donor
sixteen
patient
treat
vstskg
median
day
infus
safe
reconstitut
suffici
antivir
immun
enabl
addit
antivir
drug
avoid
eight
patient
final
gottlieb
et
al
report
phase
ii
studi
gener
use
either
dc
dc
transduc
adenovir
vector
encod
full
length
antigen
total
patient
receiv
singl
dose
day
outcom
compar
group
contemporan
control
differ
acut
chronic
gvhd
group
overal
surviv
similar
howev
reduct
percentag
patient
requir
antivir
therapi
versu
total
number
treatment
day
vst
cohort
day
versu
day
thu
vst
direct
benefit
preventingtr
cmv
reactiv
reduc
requir
antivir
therapi
correspond
reduct
drug
cost
drug
morbid
increas
practic
use
adopt
transfer
cell
extend
applic
addit
virus
develop
protocol
gener
vst
simultan
activ
multipl
agent
gener
vst
direct
common
seriou
viral
infect
cmv
adv
ebv
prepar
apc
consist
activ
monocyt
transduc
clinic
grade
adenovir
vector
either
encod
immunodomin
antigen
gener
triviru
vst
cmv
seroposit
donor
modifi
null
vector
gener
vst
cmv
seroneg
donor
thu
present
viral
antigen
deriv
transform
ebv
transduc
adenovir
vector
encod
cmv
transgen
use
stimul
donor
pbmc
doubl
lcl
consist
reactiv
polyclon
vst
activ
target
virus
singl
cultur
administ
small
number
vitro
expand
biviru
triviru
vst
recipi
age
rang
year
haploident
relat
unrel
donor
transplant
none
develop
gvhd
postinfus
observ
detect
increas
precursor
frequenc
cell
direct
ebv
cmv
peripher
blood
circul
cell
increas
recipi
also
evid
adv
infect
demonstr
import
vivo
restimul
viral
antigen
support
expans
infus
cell
also
saw
evid
activ
three
virus
vivo
ten
patient
cmv
reactiv
defin
increas
cmv
dna
cmv
antigen
posit
complet
partial
respons
defin
reduct
viral
load
vst
coincid
increas
cell
similarli
seven
patient
evid
ebv
reactiv
includ
also
respond
vst
mark
expans
cell
final
six
eight
recipi
adv
infect
defin
cultur
posit
respiratori
tract
blood
stool
diseas
time
vst
infus
mark
reduct
adenovir
load
concomit
rise
frequenc
circul
cell
includ
one
patient
progress
adenovir
pneumonia
requir
maxim
ventilatori
support
complet
respons
vst
clearanc
adv
respiratori
tract
result
summar
tabl
also
noteworthi
neither
biviru
triviru
vst
recipi
develop
de
novo
adv
infect
contrast
incid
similar
patient
receiv
vst
suggest
infus
cell
may
surviv
level
threshold
detect
protect
patient
long
term
perhap
enter
memori
pool
possibl
support
abil
detect
cell
singl
ex
vivo
restimul
blood
cell
adenovir
antigen
henc
broad
spectrum
antivir
protect
treatment
provid
singl
infus
cell
small
number
cell
provid
antivir
protect
reduc
cost
allevi
concern
associ
use
live
virusvir
vector
manufactur
vst
investig
altern
sourc
antigen
stimul
donor
pbmc
replac
adenovector
gener
dna
plasmid
encod
immunogen
antigen
ebv
cmv
adv
hexon
penton
could
introduc
apc
dc
use
clinic
accept
amaxa
nucleofect
system
preclin
studi
achiev
high
level
transgen
express
follow
nucleofect
dc
good
viabil
period
activ
reproduc
gener
vst
phenotyp
similar
convent
gener
vst
mix
cell
proport
retain
express
central
memori
marker
contain
cell
frequenc
compar
superior
convent
product
clinic
grade
rapidli
produc
scalabl
quantiti
excel
stabil
sinc
plasmid
integr
poorli
transfect
cell
genom
approach
also
allevi
safeti
concern
thu
transit
antigen
sourc
would
substanti
lower
product
cost
vst
recent
evalu
direct
stimul
donor
pbmc
commerci
avail
peptid
mixtur
pepmix
consist
peptid
librari
deriv
viral
antigen
overlap
amino
acid
sinc
peptid
amino
acid
length
pepmix
cover
possibl
major
epitop
vst
phenotyp
function
equival
convent
gener
vst
refin
elimin
need
dc
special
apc
virusvir
vector
stimul
result
reduct
manufactur
cost
convent
vst
made
sequenti
expans
step
tradit
plate
weekli
restimul
regular
split
cultur
cell
system
extrem
labor
intens
highli
skill
essenti
unscal
frequent
media
chang
requir
optim
nutrient
cytokin
level
remov
wast
product
make
contamin
constant
risk
still
allow
cell
undergo
signific
cell
death
effort
substitut
close
scalabl
bioreactor
system
wide
use
type
clinic
cell
cultur
system
fail
produc
vst
specif
effector
function
address
logist
issu
collabor
wilson
wolf
manufactur
develop
new
dispos
ga
permeabl
rapid
expans
devic
dramat
reduc
apoptosi
cultur
result
effici
vitro
expans
static
devic
ga
exchang
occur
across
ga
permeabl
silicon
membran
base
allow
initi
input
media
volum
increas
turn
increas
avail
nutrient
dilut
wast
product
without
need
cultur
agit
frequent
cultur
feed
continu
medium
perfus
optim
growth
condit
allow
higher
densiti
per
unit
surfac
area
achiev
per
compar
approxim
per
well
incorpor
platform
substanti
simplifi
vst
product
minim
number
complex
cell
manipul
without
affect
phenotyp
function
gener
line
recent
maximum
three
virus
could
success
target
singl
vst
effort
make
vst
consist
specif
addit
virus
founder
problem
antigen
competit
phenomenon
occur
due
competit
peptid
becom
bound
hla
molecul
express
share
apc
physic
constraint
capac
apc
simultan
engag
cell
differ
specif
present
substanti
differ
frequenc
inde
even
convent
triviru
ebvcmvadv
vst
describ
domin
cell
expens
ebv
compon
breadth
adv
epitop
recogn
magnitud
respons
less
triviru
product
biviru
product
gener
use
transduc
adenovir
vector
lack
transgen
antigen
competit
result
product
line
restrict
viral
specif
preclud
gener
potent
effector
cell
would
effect
complet
array
pathogen
present
hsct
recipi
convent
vst
manufactur
process
incorpor
exogen
cytokin
discov
advers
affect
vst
prolifer
surviv
vitro
increas
suscept
cell
death
aicd
contribut
restrict
repertoir
epitop
recognit
thu
increas
rang
viral
antigen
could
recogn
singl
vst
line
therebi
mitig
impact
antigen
competit
supplement
cultur
pbmc
cytokin
shown
support
prolifer
vitro
vivo
well
cytokin
combin
support
retent
central
memori
phenotyp
promot
activ
surviv
upregul
molecul
line
supplement
observ
expans
surviv
cell
within
pbmc
recogn
multipl
viral
epitop
kill
target
induc
cell
despit
exposur
prototyp
cytokin
importantli
vst
cultur
lack
alloreact
cell
even
vst
produc
singl
vitro
stimul
viral
peptid
approach
abl
allevi
antigen
competit
within
apc
cell
learn
whether
manufactur
modif
produc
clinic
activ
vst
perform
well
better
convent
gener
vst
initi
two
clinic
studi
first
clinic
trial
assess
safeti
potenc
triviru
vst
produc
use
dc
apc
follow
expans
day
devic
media
supplement
rapidli
gener
triviru
vst
infus
allogen
hsct
recipi
five
haploident
four
match
unrel
donor
one
mismatch
unrel
donor
one
match
relat
donor
activ
infect
one
target
virus
cmv
adv
ebv
ebvadv
cmvadv
patient
receiv
day
one
patient
develop
mild
local
skin
rash
postinfus
patient
also
intercurr
bk
infect
present
similar
rash
earlier
episod
bk
reactiv
toxic
note
overal
clinic
respons
rate
equival
achiev
previou
trial
cell
gener
use
ebv
adv
vector
manufactur
subject
activ
adv
cmv
andor
ebv
infect
measur
increas
circul
cell
direct
infect
viru
es
clearanc
singl
dual
viral
reactivationdiseas
importantli
line
studi
gener
without
exposur
biohazard
live
virusvir
vector
manufactur
day
versu
week
convent
vst
ml
peripher
blood
without
evid
loss
efficaci
recent
initi
clinic
trial
base
around
manufactur
simplif
donor
pbmc
stimul
pepmix
combin
span
immunogen
antigen
five
clinic
relev
virus
ebv
cmv
adv
bk
follow
expans
day
devic
use
media
supplement
date
infus
pentaval
p
vst
allogen
hsct
recipi
dose
rang
immedi
infusion
toxic
de
novo
acut
gvhd
studi
still
ongo
date
infus
pvst
success
control
activ
infect
associ
five
target
virus
thu
appear
rapidli
produc
day
vst
target
five
clinic
relev
pathogen
gener
ml
peripher
blood
produc
clinic
benefit
current
explor
extens
platform
includ
addit
clinic
relev
virus
manufactur
modif
describ
help
vst
therapi
becom
standard
care
transplant
recipi
facilit
adopt
approach
sponsor
late
phase
clinic
studi
gener
product
cord
blood
infus
complic
low
number
avail
cell
naiv
phenotyp
associ
low
frequenc
cell
henc
gener
vst
vitro
requir
use
donor
dc
profession
apc
addit
enhanc
cytokin
whether
cell
vivo
persist
antivir
activ
vst
gener
seroposit
donor
peripher
blood
remain
seen
last
report
hanley
et
al
american
societi
hematolog
annual
meet
seven
patient
receiv
day
cord
blood
transplant
toxic
subsequ
gvhd
five
patient
initi
infect
reactiv
episod
two
patient
evid
cmv
ebv
reactiv
control
although
cmv
two
vst
infus
requir
thu
earli
report
indic
infus
cord
blood
deriv
cell
support
immun
reconstitut
vivo
despit
clinic
benefit
associ
vst
therapi
eas
manufactur
afford
product
refin
need
gener
specif
vst
individu
patient
render
approach
impract
widespread
urgent
use
donor
lack
viral
immun
cord
blood
transplant
describ
circumv
requir
investig
prepar
administ
bank
close
vst
shelf
product
avail
immedi
use
administr
product
howev
associ
concern
line
administ
mismatch
one
may
either
increas
gvhd
postinfus
due
alloreact
line
reduc
vivo
persist
antivir
benefit
due
alloreact
recipi
despit
concern
number
studi
shown
approach
feasibl
safe
effect
report
high
level
clinic
respons
exampl
haqu
et
al
use
third
parti
vst
treat
ptld
solid
organ
hsct
transplant
studi
patient
receiv
four
dose
vstskg
weekli
interv
line
select
match
low
resolut
type
screen
high
level
kill
donor
low
level
kill
pha
blast
patient
develop
organ
reject
gvhd
studi
show
respons
rate
week
month
respect
degre
hla
match
line
recipi
rang
hla
antigen
month
statist
signific
trend
toward
better
outcom
closer
match
second
report
two
solid
organ
transplant
recipi
cn
lymphoma
receiv
close
match
cell
lead
complet
resolut
brain
lesion
due
similarli
memori
sloan
ketter
group
report
third
parti
vst
produc
complet
respons
four
five
patient
ebv
ptld
hsct
includ
two
cord
blood
transplant
recipi
recent
group
appli
approach
treat
patient
refractori
cmv
adv
ebv
infect
multicent
studi
establish
bank
vst
use
convent
manufactur
approach
administ
recipi
allogen
hsct
marrow
n
peripher
blood
n
cord
blood
n
singl
doubl
unit
bank
suffici
size
us
identifi
suitabl
line
patient
screen
particip
line
infus
chosen
base
presenc
activ
infect
viru
share
hla
allel
requir
comprehens
analysi
viral
epitop
vst
identif
hla
restrict
element
associ
activ
infect
viru
share
hla
allel
confirm
select
best
line
base
overal
degre
hla
match
patient
treat
complet
partial
respons
cmv
adv
ebv
major
durabl
tabl
vivo
persist
monitor
use
deep
sequenc
analysi
indic
donor
tcr
sequenc
becam
appar
concomit
reduct
viral
titer
persist
week
postinfus
although
beyond
month
analysi
perform
expect
third
parti
cell
elimin
concomit
endogen
immun
recoveri
inde
patient
treat
requir
vst
sustain
clinic
benefit
howev
saw
signific
de
novo
gvhd
one
episod
secondari
graft
failur
patient
relaps
thu
studi
like
applic
bank
vst
observ
associ
increas
toxic
sinc
avail
clinic
data
support
safeti
clinic
activ
third
parti
vst
possibl
use
bank
larger
scale
particularli
given
avail
rapid
vst
manufactur
technolog
see
section
manufactur
limit
vst
therebi
make
adopt
transfer
vst
standard
care
transplant
recipi
third
parti
cell
may
use
immedi
measur
need
specif
vst
assess
necessari
addit
product
made
like
vst
increas
role
play
prevent
manag
viral
infect
abil
rapidli
select
vst
virus
cmv
ebv
rel
rapidli
cultur
cell
line
specif
broad
rang
common
viral
antigen
coupl
feasibl
develop
shelf
vst
ensur
advantag
approach
compar
avail
small
molecul
therapi
becom
increasingli
evid
